Patent intelligence · US
US 11286463
Reprogramming of aged adult stem cells
Reprogramming of aged adult stem cells
Patent details — US 11286463
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 29, 2022
- Expiration
- Mar 24, 2042
- Applicant
- Advanced ReGen Medical Technologies, LLC
- Claims
- 18
- CPC classes
- A61K, A61K35/12
Quick answer
US 11286463 (Reprogramming of aged adult stem cells) is held by Advanced ReGen Medical Technologies, LLC. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Advanced ReGen Medical Technologies, LLC
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K35/12
More from Advanced ReGen Medical Technologies, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11286463?
US 11286463 (Reprogramming of aged adult stem cells) is held by Advanced ReGen Medical Technologies, LLC. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11286463?
Advanced ReGen Medical Technologies, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11286463 expire?
Our index shows an expiration date of Mar 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.